Venture&Growth Archives - Gilde Healthcare

Menu
Menu
Home

Neuigkeiten & Einblicke
Venture&Growth

Gilde Healthcare company Moximed reports treatment of first commercial patients post FDA approval

Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement Multiple surgeons from multiple U.S. centers treat patients with knee osteoarthritis
6. September 2023

Gilde Healthcare company Withings launches its next-generation scanwatch with enhanced sensors to monitor additional health metrics 24/7

test Withings introduces the hybrid watch that watches your health day and night with new capabilities to monitor body temperature 24/7, heart rate variability, respiratory rate and female menstrual cycles

Volta Medical Announces Initiation of RESTART Clinical Trial for Treatment of Repeat Atrial Fibrillation

test Interventional study to evaluate long term outcomes of Volta’s AI solution-supported ablation in recurrent-AF patients who failed previous ablation International, multi-center trial at 21 sites with results expected in 2025 Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists in treating complex cardiac arrhythmias such as atrial fibrillation (AF), […]

Tagworks Pharmaceuticals announces $64 Million in Series A financing co-led by Gilde Healthcare

Tagworks Pharmaceuticals BV (“Tagworks”), the Dutch pioneer of Click-to-Release chemistry designed to deliver more effective and safer systemic therapies, today announced a $64 million Series A financing led by Gilde Healthcare and Ysios Capital and with participation from international investors Novartis Venture Fund, New Enterprise Associates (NEA),...

Noema Pharma Appoints Ilise Lombardo, M.D., as Chief Executive Officer

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Ilise Lombardo, M.D., as Chief Executive Officer of the Company. “We are very excited that Ilise will be stepping into the CEO role at Noema Pharma. Ilise has the...

Gilde Healthcare legt sechsten Venture & Growth Fonds mit einem Volumen von 600 Millionen EUR für Investitionen in Europa und Nordamerika auf

Ein ausgewogener Mix internationaler Investoren stellt 600 Millionen Euro für den transatlantisch investierenden Gilde Healthcare Venture&Growth VI zur Verfügung Gilde Healthcare investiert in schnell wachsende Unternehmen, die eine verbesserte Gesundheitsversorgung bei gleichzeitig geringeren Kosten zum Ziel haben. Dabei wird Gilde von seinem unlängst ernannten Impact Council unterstützt...

Gilde Healthcare portfolio company Moximed obtains FDA Market Authorization of the MISHA™ Knee System for People Suffering from Knee Osteoarthritis

Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement MISHA Knee System is implanted during an outpatient procedure; it’s the first and only device of its kind for people with symptomatic knee OA  More than 32 million...

Gilde Healthcare company Adcendo announces extension of series A financing to EUR 82M to develop its first-in-class ADC pipeline

Gilde Healthcare portfolio company Adcendo Aps (‘Adcendo’), focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful completion of a Series A extension financing, raising a further EUR 31M, following the EUR 51M...

GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing Led by Gilde Healthcare

GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, announced that it has raised $45 million in a Series C financing led by Gilde Healthcare Partners with participation from existing institutional investors MVM Partners, MedTech Venture Partners, and...
Loading...
These were all messages
56fe76ef55